GraniteShares Advisors LLC Sells 430 Shares of Johnson & Johnson (NYSE:JNJ)

GraniteShares Advisors LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,444 shares of the company’s stock after selling 430 shares during the quarter. GraniteShares Advisors LLC’s holdings in Johnson & Johnson were worth $1,232,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rather & Kittrell Inc. raised its holdings in Johnson & Johnson by 2.0% during the 2nd quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock worth $481,000 after purchasing an additional 58 shares during the last quarter. Capital Square LLC increased its stake in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock valued at $703,000 after acquiring an additional 58 shares during the last quarter. Wagner Wealth Management LLC increased its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after acquiring an additional 59 shares during the last quarter. Chesapeake Wealth Management increased its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock valued at $1,522,000 after acquiring an additional 60 shares during the last quarter. Finally, MTM Investment Management LLC increased its stake in shares of Johnson & Johnson by 0.5% in the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock valued at $1,749,000 after acquiring an additional 61 shares during the last quarter. 68.40% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $149.91 on Tuesday. The stock has a market capitalization of $360.88 billion, a P/E ratio of 11.13, a P/E/G ratio of 3.00 and a beta of 0.58. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $181.04. The company has a 50 day moving average of $154.52 and a 200-day moving average of $160.29. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The business had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. As a group, equities research analysts forecast that Johnson & Johnson will post 10.1 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be paid a $1.19 dividend. The ex-dividend date is Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio is presently 35.34%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Friday. Wells Fargo & Company lowered their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research note on Thursday, August 31st. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday. Atlantic Securities increased their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, HSBC initiated coverage on Johnson & Johnson in a research note on Wednesday, September 6th. They set a “hold” rating and a $175.00 target price for the company. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.